Skip to main content

Table 1 Baseline characteristics of the 30 patients enrolled in the study

From: Botulinum toxin injections as an effective treatment for patients with intertriginous Hailey-Hailey or Darier disease: an open-label 6-month pilot interventional study

  HHD & DD—n (%): 30 (100) HHD—n (%): 26 (86.7) DD—n (%): 4 (13.3)
Patients’ characteristics
Age—Mean (± SD) [min–max] 55.8 (± 15.5) [21.6–77.6] 56.2 (± 16) [21.6–77.6] 54.1 (± 13.6) [42–68.5]
Sex Ratio (F/M) 1 1 1
Family history of disease—n (%) 24 (80) 21 (80.8) 3 (75)
Age at first signs (Y)—Mean (± SD) [min—max] 28.9 (± 13.9) [8–72] 29.5 (± 14) [8–72] 24.8 (± 14.5) [13–44]
Age at diagnosis (Y)—Mean (± SD) [min—max] 41 (± 17.2) [14–73] 41.8 (± 17.1) [18–73] 35.3 (± 19.6) [14–58]
Duration of the disease (Y)—Mean (± SD) [min—max] 27.1 (± 16.5) [0.6–59.5] 26.7 (± 17.7) [0.6–59.5] 29.3 (± 4.3) [24.5–34.8]
Previous treatments
Topical treatments—n (%) 30 (100) 26 (100) 4 (100)
Antiseptics, emollients, antibiotics 30 (100) 26 (100) 4 (100)
Steroids 30 (100) 26 (100) 4 (100)
Tacrolimus 7 (23) 7 (27) 0 (0)
Systemic treatments—n (%) 18 (60) 15 (58) 3 (75)
Antibiotics 17 (57) 15 (58) 2 (50)
Retinoids 3 (10) 1 (4) 2 (50)
Steroids 3 (10) 3 (10) 0 (0)
Antihistamines 2 (7) 2 (7) 0 (0)
Interventional treatments—n (%) 13 (43) 9 (35) 4 (100)
Botulinum toxin 6 (20) 5 (19) 1 (25)
CO2 laser (laser ablation) 7 (23) 5 (19) 2 (50)
Surgical dermabrasion 1 (3) 1 (3) 0 (0)
Photodynamic therapy 8 (27) 5 (19) 3 (75)
Disease characteristics
Characteristics of the selected areas
Number—Mean (± SD) [min—max] 3 (± 1.2) [1–7] 3 (± 1.3) [1–7] 2.8 (± 1) [2–4]
Location—n (%)
Axillary fold (uni- or bilateral) 23 (77) 20 (77) 3 (75)
Inguinal fold (uni- or bilateral) 20 (67) 17 (65) 3 (75)
Mammary fold (uni- or bilateral) 7 (23) 5 (19) 2 (50)
Abdominal apron 3 (10) 2 (8) 1 (25)
Disease severity—Mean (± SD) [min—max]
Total surface area (cm2) 271.7 (± 208.2) [43–995] 271 (± 220.6) [43–995] 276.3 (± 115.3) [120–398]
Global severity (score/4) 2.89 (± 0.68) [2–4] 2.86 (± 0.69) [2–4] 3.04 (± 0.67) [2.5–4]
Quality of life and psycho-social impairment
DLQI (score/30)—Mean (± SD) [min–max] 13 (± 6.84) [1–26] 13.35 (± 6.4) [1–26] 10.75 (± 10.14) [1–20]
DLQI > 10—n (%) 20 (66.7) 18 (69) 2 (50)
HidroQoL (score/36)—Mean (± SD) [min—max] 18.3 (± 7.8) [5–35] 18.62 (± 7.86) [5–35] 16.25 (± 8.14) [7–26]
Functional symptoms—Mean (± SD) [min–max]
Itchiness (VAS/10) 4.3 (± 2.71) [0–10] 4.05 (± 2.79) [0–10] 5.88 (± 1.44) [5–8]
Cutaneous pain (VAS/10) 4.63 (± 2.86) [0–9] 4.8 (± 2.69) [0–9] 3.53 (± 4.07) [0–7.1]
Sweating (VAS/10) 5.8 (± 2.65) [0–10] 5.64 (± 2.78) [0–10] 6.88 (± 1.31) [5–8]
Odour (VAS/10) 4.79 (± 3.05) [0–10] 4.46 (± 3.09) [0–10] 6.93 (± 1.72) [5–8.7]
Skin infections during the 6 months preceding the injections
Number of episodes—Mean (± SD) [min–max] 5.69 (± 8.16) [0–40] 5.44 (± 8.33) [0–40] 7.25 (± 7.89) [0–18]
  1. Legend: D: Darier disease; DLQI: Dermatology Life Quality Index; F: Female; HHD: Hailey-Hailey disease; HidroQoL: Hyperhidrosis Quality of life index; M: Male; [min—max]: [minimum—maximum]; n: number of patients; %: percentage; SD: Standard Deviation; VAS: Visual Analogue Scale; Y: year